GSK-3 inhibitors: Recent developments and therapeutic potential

Current Signal Transduction Therapy

Volumn 3, Issue 3, 2008, Pages 195-205

  Kaku, Shinsuke ^a   Chaki, Shigeyuki ^a   Muramatsu, Makoto ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Bipolar disorder; Diabetes; GSK 3; GSK 3 inhibitors

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 603281 21 8; ANTIDEPRESSANT AGENT; AR A 014418; AR A 025028; CT 118637; CT 20026; CT 98014; CT 98024; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HYMENIALDISINE; INDIRUBIN; INSULIN RECEPTOR SUBSTRATE 1; L 803 MTS; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NP 031112; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WNT PROTEIN; ZINC;

ALOPECIA; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; APOPTOSIS; BIPOLAR DISORDER; CELL ASSAY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG INDUSTRY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DYSLIPIDEMIA; ELECTROCONVULSIVE THERAPY; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME PURIFICATION; EXPERIMENTAL MODEL; GLYCOGEN METABOLISM; HUMAN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCHIZOPHRENIA; SEPTIC SHOCK; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

EID: 54849441461     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208785699712     Document Type: Review

References (127)

1. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochem Biophys Acta 1992; 1114: 147-62.
2. Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 1991; 200: 564-77.
3. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/Factor A. EMBO J 1990; 9: 2431-438.
4. Lau KF, Miller CC, Anderton BH, Shaw PC. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 1999; 54: 85-91.
5. Leroy K, Brion JP. Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J Chem Neuroanat 1999; 16: 279-93.
6. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J Neurochem 2002; 81: 1073-83.
7. Schaffer B, Wiedau-Pazos M, Geschwind DH. Gene structure and alternative splicing of glycogen synthase kinase 3β(GSK-3β) in neural and non-neural tissues. Gene 2003; 302: 73-81.
8. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279: 39541-54.
9. Harwood AJ. Regulation of GSK-3: A Cellular Multiprocessor. Cell 2001; 105: 821-24.
10. Cho J-H, Johnson GVW. Glycogen Synthase Kinase 3β Phosphorylates Tau at Both Primed and Unprimed Sites. J Biol Chem 2003; 278: 187-93.
11. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-86.
12. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377: 249-55.
13. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A Chaperone-Dependent GSK3β Transitional Intermediate Mediates Activation-Loop Autophosphorylation. Mol Cell 2006; 24: 627-33.
14. Ryves WJ, Harwood AJ. Related Articles, Links Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001; 280: 720-5.
15. Hong M, Chen DC, Klein PS, Lee VM. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997; 272: 25326-32.
16. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tanopathy and degeneration in vivo. Proc Natl Acad Sci U S A 2005; 102: 6990-5.
17. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003; 423: 435-9.
18. Haugaard ES, Mickel RA, Haugaard N. Actions of lithium ions and insulin on glucose utilization, glycogen synthesis and glycogen synthase in the isolated rat diaphragm. Biochem Pharmacol 1974; 23: 1675-85.
19. Cheng K, Creacy S, Larner J. 'Insulin-like' effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase. Mol Cell Biochem 1983; 56: 183-9.
20. Summers SA, Kao AW, Kohn AD, et al. The role of glycogen synthase kinase 3β in insulin-stimulated glucose metabolism. J Biol Chem 1990; 274: 17934-40.
21. Orena SJ, Torchia AJ, Garofalo RS. Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 2000; 275: 15765-72.
22. Fürnsinn C, Noe C, Herdlicka R, et al. More marked stimulation by lithium than insulin of the glycogenic pathway in rat skeletal muscle. Am J Physiol Endocrinol Metab 1997; 273: E514-20.
23. Tabata I, Schluter J, Gulve EA, Holloszy JO. Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes 1994; 43: 903-7.
24. Chen X, McMahon EG, Gulve EA. Stimulatory effect of lithium on glucose transport in rat adipocytes it not mediated by elevation of IPI. Am J Physiol Endocrinol Metab 1998; 275: E272-7.
25. Saran AS. Antidiabetic effects of lithium. J Clin Psychiatry 1982; 43: 383-4.
26. Rossetti L. Normalization of insulin sensitivity with lithium in diabetic rats. Diabetes 1989; 38: 648-52.
27. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-9.
28. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 β (GSK3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002; 45: 1292-9.
29. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci 2007; 27: 5766-76.
30. Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003; 278: 45937-45.
31. Wang W, Yang Y, Ying C, et al. Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007; 52: 1678-84.
32. Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10: 1255-66.
33. Leclerc S, Garnier M, Hansel R, et al. Indirubins inhibit glycogen synthase kinase-3 β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001; 276: 251-60.
34. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK-3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10: 1105-37.
35. Kunick C, Lauenroth K, Wieking K, et al. Evaluation and comparison of 3DQSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. J Med Chem 2004; 47: 22-36.
36. Pettit GR. Progress in the discovery of biosynthetic anticancer drugs. J Nat Prod 1996: 812-21.
37. Meijer L, Thunnissen AM, White AW, et al. Inhibition of cyclin-dependent kinases, GSK3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000; 7: 51-63.
38. Hers I, Tavaré JM, Denton RM. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett 1999; 460: 433-6.
39. Coghlan MP, Culbert AA, Cross DAE, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000; 7: 793-803.
40. Ring DB, Johnson KW, Henriksen EJ, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003; 52: 588-95.
41. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000; 49: 263-71.
42. Dokken BB, Sloniger JA, Henriksen EJ. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E1188-94.
43. Dokken BB, Henriksen EJ. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats. Am J Physiol Endocrinol Metab 2006; 291: E207-13.
44. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
45. Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 1987; 262: 14042-8.
46. Fiol CJ, Wang A, Roeske RW, Roach PJ. Ordered multisite protein phosphorylation. Analysis of glycogen synthase kinase 3 action using model peptide substrates. J Biol Chem 1990; 265: 6061-5.
47. Zhang W, DePaoli-Roach AA, Roach PJ. Mechanisms of multisite phosphorylation and inactivation of rabbit muscle glycogen synthase. Arch Biochem Biophys 1993; 304: 219-25.
48. Plotkin B, Kaidanovich O, Tailor I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003; 305: 974-80.
49. Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther 2006; 316: 17-24.
50. Roach PJ. Glycogen and its metabolism. Curr Mol Med 2002; 2: 101-20.
51. Ferrer JC, Favre C, Gomis RR, et al. Control of glycogen deposition. FEBS Lett 2003; 546: 127-32.
52. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994; 269: 1-4.
53. Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372: 186-90.
54. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatylinositol 3-kinase activation is required for insulin stimulation off pp70, s6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994; 14: 4902-11.
55. Tsakiridis T, McDowell HE, Walker T, et al. Multiple roles of phosphatidylinositol 3-kinase in regulation of glucose-transport, amino-acid-transport, and glucose transporters in L6 skeletal-muscle cells. Endocrinology 1995; 136: 4315-22.
56. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997; 7: 261-9.
57. Hajduch E, Alessi DR, Hemmings BA, Hundal HS. Constitutive activation of protein kinase B α by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 1998; 47: 1006-13.
58. Cross DA, Watt P, Shaw M, et al. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett 1997; 406: 211-5.
59. Markuns JF, Wojtaszewski JF, Goodyear LJ. Insulin and exercise decrease glycogen synthase kinase-3 activity by different mechanisms in rat skeletal muscle. J Biol Chem 1999; 274: 24896-900.
60. Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 1993; 294: 625-9.
61. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
62. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 1999; 48: 1662-6.
63. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 2002; 51: 2190-8.
64. Pearce NJ, Arch JR, Clapham JC, et al. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter. Metabolism 2004; 53: 1322-30.
65. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate I by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 1997; 94: 9660-4.
66. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-7.
67. Qiao LY, Zhande R, Jetton TL, Zhou G, Sun XJ. In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem 2002; 277: 26530-9.
68. Moeschel K, Beck A, Weigert C, et al. Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-I (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem 2004; 279: 25157-63.
69. Mothe I, Van Obberghen E. Phosphorylation of insulin receptor substrate-I on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem 1996; 271: 11222-7.
70. Waraich RS, Weigert C, Kalbacher H, et al. Phosphorylation of Ser357 of Rat Insulin Receptor Substrate-1 Mediates Adverse Effects of Protein Kinase C-{delta} on Insulin Action in Skeletal Muscle Cells. J Biol Chem 2008; 283: 11226-33.
71. Liberman Z, Eldar-Finkelman H. Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J Biol Chem 2005; 280: 4422-8.
72. Dokken BB, Saengsirisuwan V, Kim JS, Teachey MK, Henriksen EJ. Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3. Am J Physiol Endocrinol Metab 2008; 294: E615-21.
73. Wimo A, Jonsson L, Winblad B. An Estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21: 175-81.
74. Kypta RM. GSK-3 inhibitors and their potential in the treatment of Alzheimer's disease. Expert Opin Ther Patents 2005; 15: 1315-31.
75. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91.
76. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Aβ42 fibrils. Science 2001; 293: 1491-5.
77. Suh YH, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 2002; 54: 469-525.
78. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120: 545-55.
79. Yoshida S, Maeda M, Kaku S, Ikeya H, Yamada K, Nakaike S. Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus. J Neural Transm 2006; 113: 1803-14.
80. Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002; 277: 44701-8.
81. Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 2005; 118: 89-99.
82. King TD, Bijur GN, Jope RS. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3β and attenuated by lithium. Brain Res 2001; 919: 106-14.
83. Schäfer M, Goodenough S, Moosmann B, Behl C. Inhibition of glycogen synthase kinase 3β is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 2004; 1005: 84-9.
84. Facci L, Stevens DA, Skaper SD. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 2003; 14: 1467-70.
85. Farias GG, Godoy JA, Hernanández F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 2004; 17: 337-48.
86. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2084; 89: 1313-7.
87. Chen G, Huang LD, Jiang YM, Manji BK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-30.
88. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29: 1426-31.
89. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005; 57: 533-42.
90. Roh MS, Kang UG, Shin SY, et al. Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3β after electroconvulsive shock in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1-5.
91. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 2003; 55: 1143-7.
92. Nowak G, Szewczyk B, Wieronska JM, et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 2003; 61: 159-64.
93. An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei JJ. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3β in SH-SY5Y neuroblastoma cells. J Neurochem 2005; 92: 1104-15.
94. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004; 101: 5099-104.
95. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-90.
96. Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3β: a putative model of hyperactivity and mania. J Neurosci 2006; 26: 9022-9.
97. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781-4.
98. O'Brien WT, Harper AD, Jové F, et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24: 6791-8.
99. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004; 29: 32-8.
100. Madsen TM, Newton SS, Eaton ME, Russell DS, Duman RS. Chronic electroconvulsive seizure up-regulates β-catenin expression in rat hippocampus: role in adult neurogenesis. Biol Psychiatry 2003; 54: 1006-14.
101. Gould TD, Einat H, O'donnell KC, Picchini AM, Schloesser RJ, Manji HK. β-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 2007; 32: 2173-83.
102. Bondy CA, Cheng CM. Signaling by insulin-like growth factor I in brain. Eur J Pharmacol 2004; 490: 25-31.
103. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
104. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-8.
105. Malberg JE, Platt B, Rizzo SJ, et al. Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects. Neuropsychopharmacology 2007; 32: 2360-8.
106. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
107. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida S, Kikuchi A. Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3β-dependent phosphorylation of beta-catenin and down-regulates β-catenin. J Biol Chem 2000; 275: 34399-406.
108. Johnson CD, Puntis M, Davidson N, Todd S, Bryce R. Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br J Surg 2001; 88: 662-8.
109. Gould TD, Gray NA, Manji HK. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res 2003; 48: 49-53.
110. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65: 2076-81.
111. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Glycogen synthase kinase-3β activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004; 145: 2941-9.
112. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004; 23: 7882-92.
113. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3β in prostate cells. J Biol Chem 2004; 279: 32444-52.
114. Iwahana E, Akiyama M, Miyakawa K, et al. Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei. Eur J Neurosci 2004; 19: 2281-7.
115. Iitaka C, Miyazaki K, Akaike T, Ishida N. A role for glycogen synthase kinase-3β in the mammalian circadian clock. J Biol Chem 2005; 280: 29397-402.
116. Harada Y, Sakai M, Kurabayashi N, Hirota T, Fukada Y. Ser-557-phosphorylated mCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3β. J Biol Chem 2005; 280: 31714-21.
117. Kulkarni NH, Onyia JE, Zeng QQ, et al. Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006; 21: 910-20.
118. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
119. Kaisho T, Akita S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117: 979-87.
120. Martin M, Rehani K, Jope KS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777-84.
121. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-67.
122. Greenwood HL, Singer PA, Downey GP, Martin DK, Thorsteinsdóttir H, Daar AS. Regenerative medicine and the developing world. PLoS Med 2006; 3: e381.
123. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63.
124. Ding S, Wu TY, Brinker A, et al. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci USA 2003; 100: 7632-7.
125. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 2006; 12: 89-98.
126. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371: 199-204.
127. Cline GW, Johnson K, Regittnig W, et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats I: Diabetes 2002; 51: 2903-10.